Skip to search formSkip to main contentSkip to account menu

Parnaparin sodium

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
What is known and Objective:  The most common complication of heparin therapy is bleeding. Allergic reactions to heparin are rare… 
2010
2010
CB-01-05-MMX (LMW Heparin MMX), being developed by Cosmo Pharmaceuticals SpA, is a novel oral parnaparin sodium formulation for… 
2008
2008
Background  Efficacy of heparin and low‐molecular‐weight heparins (LMWHs) in inflammatory bowel disease (IBD) treatment has been… 
2006
2006
AbstractBackground: Acute myocardial infarction (AMI) is one of the most serious cardiovascular diseases, with acute ST-segment… 
2005
2005
BACKGROUND This study sought to compare the efficacy of low molecular weight heparin, parnaparin and unfractionated heparin in… 
1994
1994
SummarySynopsisParnaparin is a low molecular weight (LMW) heparin which, like other members of its class, apparently demonstrates… 
1994
1994
Hemodialysis was performed on dogs, following intravenous bolus injections of LHG at dosage levels of 50, 100 and 200 IU/kg and…